New research suggests that individuals who come off new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end conventional lifestyle programs.
Research printed in a major medical journal shows that while obese people can lose about a fifth of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month once they quit.
"Users using these drugs should be aware of the danger of quick weight regain when the treatment ends," cautioned expert Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment weight within about one and a half years.
Analyzing Approaches
The research, which examined 37 of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with conventional dieting.
Scientists emphasize that people who lose weight through diet and exercise generally experience a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Doctors suggest the mode of action of the injections explains the accelerated regain.
These medications imitate a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the system to generate a reduced amount of its own natural GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
The NHS advise the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, considering the likelihood of relapse, the treatment might need to be life-long.
This view is reinforced by drug manufacturers, who note that the findings "highlight the chronic character of excess weight," akin to managing conditions like diabetes.
Patient Accounts
Individuals who have come off the jabs report a intense return of hunger.
"I experienced something that goes on and you become extremely hungry," said an individual.
The struggle is compounded if users have not developed permanent lifestyle or habit changes during treatment.
Growing Interest
Recent estimates indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among females than males.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, clinicians emphasize that while the jabs are powerful tools for weight loss, they are not a magic fix and long-term success likely depends on integrated lifestyle support.
